A bioequivalence study of two brands of doxycycline capsules

Abstract

Bioequivalence of two preparations of doxycycline (Doxydar™ 100-mg capsules and Vibramycin™ 100-mg capsules) were compared in a two-way crossover study. Pharmacokinetic parameters were determined for both formulations, including area under the concentration-time curve, mean maximum plasma concentration, time to maximum concentration, half-life, and the terminal rate of elimination. Statistical analysis revealed that differences between the two formulations were not statistically significant. Quality control data, including assay and disintegration, indicated that both products met the in-house specifications. It is concluded that Doxydar 100 mg is bioequivalent to Vibramycin 100 mg.